# 2025-16030: FDA Classifies Vaginitis Germ Detection Device as Safe

2025-16030, Medical Devices; Immunology and Microbiology Devices; Classification of the Device That Detects Nucleic Acid Sequences From Microorganisms Associated With Vaginitis and Bacterial Vaginosis, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-08-21, effective affects companies making or selling these devices starting now (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2025-16030
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-16030
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Device That Detects Nucleic Acid Sequences From Microorganisms Associated With Vaginitis and Bacterial Vaginosis
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 40726
- Published: 2025-08-21
- Effective: affects companies making or selling these devices starting now
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

FDA Classifies Vaginitis Germ Detection Device as Safe

## Summary

The FDA is officially putting a new test that spots germs causing vaginitis and bacterial vaginosis into a safer, middle-level category called Class II. This means the device will follow special safety rules, making sure it works well and is safe to use. This change helps patients get better access to these helpful tests faster, without extra red tape, and it affects companies making or selling these devices starting now.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is classifying the device that detects nucleic acid sequences from microorganisms associated with vaginitis and bacterial vaginosis into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the device that detects nucleic acid sequences from microorganisms associated with vaginitis and bacterial vaginosis's classification. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Vaginitis/BV Test Reclassified to Class II: benefit, medium. The FDA has classified tests that detect nucleic acid sequences from microorganisms associated with vaginitis and bacterial vaginosis into Class II (special controls). The Agency says this classification provides a reasonable assurance of safety and effectiveness and will enhance patients' access t…
- Reduced Regulatory Burden for Manufacturers: benefit, medium. The FDA's reclassification of the nucleic-acid test for vaginitis and bacterial vaginosis to Class II is intended to reduce regulatory burdens on makers and sellers of these devices. The rule affects companies making or selling these devices starting now according to the order.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2025-16030 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/21/2025-16030/medical-devices-immunology-and-microbiology-devices-classification-of-the-device-that-detects)
- [2025-16030 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-21/pdf/2025-16030.pdf)

## Related
- [Previous: 2025-16008, Rescinding Regulations on Procedures for Advance Construction of Federal-Aid Pr…](https://policyrisk.com/federal-register/2025-16008)
- [Next: 2025-16031, Medical Devices; Immunology and Microbiology Devices; Classification of the Ant…](https://policyrisk.com/federal-register/2025-16031)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-16030 (as of 2026-06-11).